Company intelligence / Profile preview

VPIX Medical

Daejeon, Daejeon, South Koreavpixmedical.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

VPIX Medical has developed and commercialized cCeLL™, a real-time digital biopsy platform that enables non-invasive, intraoperative microscopic imaging of tissue. The system is FDA-cleared and NET-certified, with clinical studies demonstrating its ability to visualize tumor margins and assist surgeons during cancer operations. Published results show effective detection of tumor cells and correlation with standard histopathology images for brain and gastric cancers.

Therapeutic areas: Oncology
Modalities: Device
Industry: Pathology

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of March–June 2025. Some academic collaborations noted below.

Beyond the preview

Go deeper on VPIX Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VPIX Medical.

Explore the full profile